Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACT3a: Chelation Therapy in Critical Limb Ischemia
NCT03982693Phase 3Active, not recruiting
- Sponsor
- Mount Sinai Medical Center
- Start
- Mar 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of edetate disodium in critical limb ischemia (CLI) (2 arms), sponsored by Mount Sinai Medical Center. Primary endpoint: Prevention of major cardiovascular endpoints at 3 years. Started Mar 2019; status: active, not recruiting.
02
Drugs
edetate disodium
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT03982693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982693.